Eli Lilly Acquires Orna Therapeutics, Boosting RNA Therapeutics Capabilities
What happened
Eli Lilly and Company acquired Orna Therapeutics, continuing its work in RNA therapeutics. Separately, CRISPR Therapeutics appointed Dr. Siva Sakhamuri as Chief Technical Officer. Dr. Sakhamuri previously served as Chief Technical Officer at Orna Therapeutics, where he led CMC and quality organizations supporting circular RNA LNP programs before the acquisition by Eli Lilly and Company in 2026.
From manilatimes.net
Why it matters
The acquisition strengthens Eli Lilly and Company's position in the advanced biopharmaceutical sector by expanding its RNA therapeutics pipeline and technical capabilities. The movement of technical leadership from Orna Therapeutics to CRISPR Therapeutics also highlights increased activity and talent transfer within the RNA therapeutics market.
From manilatimes.net
Who's involved
- Eli Lilly and CompanyAcquired Orna Therapeutics and is expanding its RNA therapeutics pipeline.
- CRISPR TherapeuticsHired Dr. Sakhamuri from Orna Therapeutics to serve as Chief Technical Officer.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
CRISPR Therapeutics
company in Basel, Switzerland
-
Alnylam Pharmaceuticals
biopharmaceutical company
Nothing else this week.
Related events
- CRISPR Therapeutics, Eli Lilly, and Johnson & Johnson are noted as major holdings in health care ETFs.
- CRISPR Therapeutics formed a strategic partnership with Vertex Pharmaceuticals.
- CRISPR Therapeutics and Vertex Pharmaceuticals split profits and costs for Casgevy, while CRISPR plans to present pipeline data at the AHA meeting.